Summit Therapeutics Inc (SMMT)

$7.93

+0.13

(+1.67%)

Market is closed - opens 7 PM, 24 Jun 2024

Insights on Summit Therapeutics Inc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 235.0K → -235.0K (in $), with an average decrease of 100.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 7 quarters, -14.71M → -43.47M (in $), with an average decrease of 22.6% per quarter

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 245.6% return, outperforming this stock by 224.7%

Performance

  • $7.75
    $8.13
    $7.93
    downward going graph

    2.26%

    Downside

    Day's Volatility :4.65%

    Upside

    2.45%

    downward going graph
  • $1.52
    $9.94
    $7.93
    downward going graph

    80.83%

    Downside

    52 Weeks Volatility :84.71%

    Upside

    20.22%

    downward going graph

Returns

PeriodSummit Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
135.31%
0.9%
0.0%
6 Months
234.6%
8.7%
0.0%
1 Year
185.25%
10.9%
0.0%
3 Years
20.88%
17.4%
-23.0%

Highlights

Market Capitalization
5.6B
Book Value
$0.06
Earnings Per Share (EPS)
0.38
PE Ratio
20.87
PEG Ratio
0.0
Wall Street Target Price
10.67
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-33.27%
Return On Equity TTM
-130.59%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
-100.0%
Gross Profit TTM
705.0K
EBITDA
-114.8M
Diluted Eps TTM
0.38
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.25
EPS Estimate Next Year
-0.29
EPS Estimate Current Quarter
-0.06
EPS Estimate Next Quarter
-0.06

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Summit Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
00
Hold
1
1
3
Sell
00
00
3

Analyst Forecast

What analysts predicted

Upside of 34.55%

Current $7.93
Target $10.67

Technicals Summary

Sell

Neutral

Buy

Summit Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Summit Therapeutics Inc
Summit Therapeutics Inc
80.64%
234.6%
185.25%
20.88%
130.52%
Moderna, Inc.
Moderna, Inc.
-18.32%
40.58%
10.72%
-39.74%
850.14%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
7.05%
24.38%
35.05%
97.21%
236.95%
Novo Nordisk A/s
Novo Nordisk A/s
5.92%
38.21%
77.43%
245.57%
453.56%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.73%
15.66%
34.62%
148.17%
158.93%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Summit Therapeutics Inc
Summit Therapeutics Inc
20.87
20.87
0.0
-0.25
-1.31
-0.33
NA
0.06
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.7
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
30.93
30.93
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.78
49.78
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
30.61
30.61
0.53
17.09
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Summit Therapeutics Inc
Summit Therapeutics Inc
Buy
$5.6B
130.52%
20.87
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$51.5B
850.14%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$115.3B
236.95%
30.93
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$644.0B
453.56%
49.78
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$121.7B
158.93%
30.61
39.46%

Institutional Holdings

  • BlackRock Inc

    1.39%
  • Vanguard Group Inc

    1.04%
  • Geode Capital Management, LLC

    0.44%
  • State Street Corporation

    0.35%
  • Northern Trust Corp

    0.16%
  • Charles Schwab Investment Management Inc

    0.14%

Company Information

summit is a uk company focused on the discovery and development of novel drug candidates to treat areas of high unmet medical need. our strategy focuses on two therapy areas: duchenne muscular dystrophy, a fatal genetic muscle wasting disease and the infectious disease caused by the bacteria c. difficile.

Organization
Summit Therapeutics Inc
Employees
105
CEO
Mr. Robert W. Duggan
Industry
Health Technology

FAQs